Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom

被引：0
|
作者：
A. Svedbom
P. Hadji
E. Hernlund
R. Thoren
E. McCloskey
R. Stad
B. Stollenwerk
机构：
[1] ICON,Centre for Metabolic Bone Diseases
[2] Frankfurt Center of Bone Disease,Centre for Integrated research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Bone Research
[3] Philips-University of Marburg,undefined
[4] University of Sheffield,undefined
[5] University of Sheffield,undefined
[6] Amgen Europe (GmbH),undefined
来源：
Osteoporosis International | 2019年 / 30卷
关键词：
Costs and costs analysis; Cost-benefit analysis; Cost-effectiveness; Osteoporosis; Osteoporotic fracture; Preventive medicine; Practice patterns;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1745 / 1754
页数：9
相关论文
共 50 条
  • [21] Correction to: The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain
    M. Chris Runken
    Paolo Caraceni
    Javier Fernandez
    Alexander Zipprich
    Rashad Carlton
    Martin Bunke
    Health Economics Review, 10
  • [22] Assessment of the cost-effectiveness of zoledronic acid in the management of skeletal metastases in lung cancer patients in France, Germany, and the United Kingdom
    Botteman, Marc F.
    Kaura, Satyin
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S542 - S543
  • [23] The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists
    Clegg, John P.
    Guest, Julian F.
    Lehman, Almut
    Smith, Andrew F.
    OPHTHALMIC EPIDEMIOLOGY, 2006, 13 (04) : 263 - 274
  • [24] The impact of COVID-19 on fertility plans in Italy, Germany, France, Spain, and the United Kingdom
    Luppi, Francesca
    Arpino, Bruno
    Rosina, Alessandro
    DEMOGRAPHIC RESEARCH, 2020, 43 : 1399 - 1412
  • [25] ADHERENCE TO TREATMENT AND PERSISTENCY IN PATIENTS TREATED WITH VKA IN FRANCE, ITALY, GERMANY, SPAIN AND THE UNITED KINGDOM
    Carrasco, J.
    Cotte, F. E.
    Lomon, Duprat, I
    Letierce, A.
    Huguet, M.
    Marchant, N.
    VALUE IN HEALTH, 2013, 16 (07) : A516 - A516
  • [26] UNDERTREATMENT OF CHRONIC MIGRAINE PATIENTS IN PRIMARY CARE IN FRANCE, GERMANY, ITALY, SPAIN AND THE UNITED KINGDOM
    Guerrero, Angel L.
    Negro, Andrea
    Ryvlin, Philippe
    Skorobogatykh, Kiril
    Sundal, Christina
    Sanchez-De La Rosa, Rainel
    MacGregor, E. Anne
    CEPHALALGIA, 2020, 40 : 33 - 33
  • [27] The cost-effectiveness of extended release tolterodine in the management of overactive bladder in Germany and the United Kingdom
    Anderson, P
    Resch, A
    Dooley, JA
    Brüggenjürgen, B
    Zlateva, G
    VALUE IN HEALTH, 2004, 7 (06) : 797 - 798
  • [28] Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom
    Joshi, Avani D.
    Carter, John A.
    Botteman, Marc F.
    Kaura, Satyin
    CLINICAL THERAPEUTICS, 2011, 33 (03) : 291 - 304
  • [29] Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia
    Mohd-Tahir, Nurul-Ain
    Thomas, Paraidathathu
    Mohamed-Said, Mohd-Shahrir
    Makmor-Bakry, Mohd
    Li, Shu-Chuen
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (03) : 647 - 655
  • [30] THE USE OF ORAL ANTICOAGULATION DRUGS FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILATION IN FRANCE, ITALY, GERMANY, SPAIN AND THE UNITED KINGDOM: IS CURRENT PRACTICE CONSISTENT WITH THE 2012 ESC RECOMMENDATIONS?
    Carrasco, J.
    Cotte, F. E.
    Lomon, Duprat, I
    Marchant, N.
    Letierce, A.
    Huguet, M.
    VALUE IN HEALTH, 2013, 16 (07) : A516 - A516
12345